Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP 692 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABP 692 | EXPERIMENTAL | Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15. A subsequent dose of 600 mg ABP 692 IV infusion will be administered 24 weeks after the initial dose. |
| Ocrelizumab (US)/ABP 692 | ACTIVE_COMPARATOR | Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (US) IV infusion on Day 1, followed by a second dose of 300 mg Ocrelizumab (US) IV infusion on Day 15. At Week 24, the treatment will switch to a 600 mg IV infusion of ABP 692. |
| Ocrelizumab (EU) | ACTIVE_COMPARATOR | Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (EU) IV infusion on Day 1, followed by a 300 mg Ocrelizumab (EU) IV infusion on Day 15. At Week 24, participants will receive a dose of 600 mg Ocrelizumab (EU) IV infusion. |
| Name | Type | Description |
|---|---|---|
| Ocrelizumab (US) | DRUG | IV infusion |
| Ocrelizumab (EU) | DRUG | IV infusion |
| ABP 692 | DRUG | IV infusion |
Inclusion Criteria: 1. Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson et al, 2018). 2. Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive. 3. Evidence of recent MS activity as defined by the study protocol. 4. Neurologically stable subject...
ABP 692 is being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS), a form of multiple sclerosis characterized by episodes of new or worsening neurological symptoms followed by periods of recovery. It is an investigational therapy and has not been approved for any indication.
ABP 692 is being developed by Amgen Inc., a biotechnology company traded on the Nasdaq under the ticker symbol AMGN. Amgen is responsible for the clinical development program evaluating ABP 692 in relapsing-remitting multiple sclerosis.
ABP 692 is in Phase 3 clinical development. The ongoing Phase 3 study is actively recruiting participants but is no longer enrolling new patients, and it is designed to compare ABP 692 with ocrelizumab in patients with relapsing-remitting multiple sclerosis.
ABP 692 is being evaluated in a single Phase 3 clinical trial, NCT06700343, titled "Comparison Between ABP 692 and Ocrevus (Ocrelizumab)." The trial has an estimated enrollment of 152 participants and is currently active but not recruiting. It is a randomized, double-blind, active-controlled study.
No, ABP 692 is not the same as Ocrevus. ABP 692 is an investigational small molecule being developed by Amgen, while Ocrevus (ocrelizumab) is a separate approved therapy. The Phase 3 trial NCT06700343 is directly comparing ABP 692 with Ocrevus in patients with relapsing-remitting multiple sclerosis.